Abcam, ab270616, Anti-BACE2 antibody [EPR23339-221] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal BACE2 antibody. Carrier free. Suitable for IP, WB, ICC/IF, IHC-Fr, IHC-P and reacts with Mouse, Human, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23339-221,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WB, ICC/IF, IP, IHC-Fr, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab270616 is the carrier-free version of
ab270458
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
BACE2 also known as beta-site APP-cleaving enzyme 2 is an aspartic acid protease. It has a molecular mass of roughly 70 kDa. This enzyme cleaves amyloid precursor protein (APP) at the beta-secretase site. BACE2 is mainly expressed in the brain but also found in other tissues like the pancreas. It shares similarity with BACE1 another protease involved in APP processing.
Biological function summary
BACE2 acts on substrates to regulate amyloidogenic processing of APP. It belongs to the peptidase A1 Family. Unlike its counterpart BACE1 which promotes amyloid-beta peptide production BACE2 has been suggested to reduce amyloid-beta formation by different substrate cleavage. Though not part of a stable complex BACE2 influences pathways related to protein processing.
Pathways
One should note that BACE2 is involved in the amyloidogenic pathway. This pathway processes APP and affects amyloid-beta levels important in neurological conditions. BACE2 acts with proteins like APP and might modulate the effects seen due to BACE1 activity. Despite overlapping functions BACE2 and BACE1 have distinct roles in this pathway impacting amyloid levels differently.
People look at BACE2 because of its connection to Alzheimer's disease and Down syndrome. BACE2 might act as a protective factor against Alzheimer's by limiting amyloid-beta accumulation. Down syndrome characterized by trisomy 21 involves heightened BACE2 expression which may modify neurodevelopment. In Alzheimer's research BACE1 has been the focus due to its role in disease progression but BACE2's contrasting effects offer a potential therapeutic angle.